Incyte Corporation (INCY) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 55/100
- 10Y CAGR
- 21.2%
- Median YoY
- 19.2%
- YoY volatility
- σ 14.1pp· uneven
- Quarters ≥ 20%
- 19 of 40
- Negative quarters
- 1
- Valuation vs own 10Y history
- P/S 4.6x · 10Y median 6.3x · 34th percentile · as of Aug 19, 2026
How this score is computed
- Quarters at or above 20%: 19 of 40 → 19 of 40 pts
- Steadiness (typical swing 14.1pp) → 14.9 of 25 pts
- Pace (median 19.2% YoY) → 5.6 of 20 pts
- Latest quarter (37.7% YoY) → 15 of 15 pts
- Score: 55 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 21.2% | 19.2% | 14.1pp | 19 of 40 | 1 |
| EPSEPS | 71% | — | — | — | — |
| Op cash flowOperating cash flow | 32.2% | 38.8% | 299.8pp | 20 of 31 | 7 |
| EBITDAEBITDA | 31.1% | 48.9% | 329.9pp | 18 of 32 | 11 |
| FCFFree cash flow | 36.4% | 48.5% | 460.5pp | 21 of 28 | 7 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: INCY on the compounders surface · All compounders, ranked